While the start of a new year often brings a flurry of JP Morgan conference headlines, the first quarter of 2026 has been quietly shaped by strategic moves and clinical wins that deserve a second look. From major leadership shifts at a pandemic-era giant to a blockbuster acquisition and key regulatory approvals, here are five key developments from the last three months that you may have missed as Q1 closes.
BioNTech Founders to Depart, Launch New mRNA Venture
In March, BioNTech co-founders Ugur Sahin and Oezlem Tuereci announced they will step down by the end of 2026 to launch a new biotechnology company. The husband-and-wife team, who led BioNTech to global prominence with its COVID-19 vaccine, will retain a significant 15% stake in the company while focusing on next-generation mRNA medicines. BioNTech will contribute certain technologies to the new venture in exchange for a minority stake and licensing fees, allowing it to continue its own strategic pivot toward oncology, where it now has more than 25 mid-to-late-stage programs underway.
Gilead to Acquire Arcellx in USD 7.8 Billion CAR-T Bet
Gilead Sciences significantly deepened its commitment to cell therapy by announcing a definitive agreement to acquire Arcellx for approximately USD 7.8 billion in its largest acquisition since 2020. The deal, which represents a 79% premium to Arcellx’s share price, builds on an existing collaboration to co-develop anito-cel, an investigational CAR T-cell therapy for multiple myeloma. Early data for anito-cel has shown “deep and durable responses,” and the acquisition gives Gilead full control of the program along with access to Arcellx’s D-Domain platform for future therapies. The transaction is expected to close in the second quarter of 2026.
Merck Scores Phase III Win for Keytruda Combination in Kidney Cancer
Merck added another important piece to its immuno-oncology franchise with positive Phase III data for a Keytruda combination in kidney cancer. The LITESPARK-022 trial showed that adding Welireg (belzutifan) to adjuvant Keytruda (pembrolizumab) following surgery reduced the risk of disease recurrence or death by 28% compared to Keytruda alone in patients with clear cell renal cell carcinoma. This marks the first time a HIF-2α inhibitor has demonstrated a benefit in combination with immunotherapy in an early-stage setting. Based on these results, the FDA has granted priority review to supplemental applications with a decision expected by June.
GSK Inks Major Licensing Deal with Frontier Biotech for siRNA Programs
GSK moved to bolster its pipeline in the RNA therapeutics space by signing an exclusive licensing agreement with China’s Frontier Biotech for two small interfering RNA (siRNA) candidates. The deal includes a USD 40 million upfront payment to Frontier, with the potential for up to USD 950 million more in development and commercial milestones. One candidate has already entered the investigational new drug application stage. Frontier will handle early clinical development in China before GSK takes over global development and commercialization, in a display of the continued flow of innovation from Asian biotech hubs to Western pharma.
Vanda Secures FDA Approval for Antipsychotic Pill Bysanti
Vanda Pharmaceuticals added a new tool to its psychiatry portfolio in February, when the US FDA approved Bysanti (milsaperidone) for the treatment of schizophrenia and acute bipolar I disorder – with the announcement sending Vanda’s shares up 30% in after-hours trading. The atypical antipsychotic works by blocking dopamine and serotonin receptors in the brain to help regulate mood and stress. The company expects to launch the drug in the US in the third quarter of 2026 and is also studying it as a potential treatment for major depressive disorder.